141 related articles for article (PubMed ID: 9103514)
1. Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.
Caraco Y; Sheller J; Wood AJ
J Pharmacol Exp Ther; 1997 Apr; 281(1):330-6. PubMed ID: 9103514
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.
Caraco Y; Sheller J; Wood AJ
J Pharmacol Exp Ther; 1996 Sep; 278(3):1165-74. PubMed ID: 8819499
[TBL] [Abstract][Full Text] [Related]
3. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects.
Caraco Y; Sheller J; Wood AJ
J Pharmacol Exp Ther; 1999 Jul; 290(1):413-22. PubMed ID: 10381807
[TBL] [Abstract][Full Text] [Related]
4. Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites.
Lötsch J; Skarke C; Schmidt H; Rohrbacher M; Hofmann U; Schwab M; Geisslinger G
Clin Pharmacol Ther; 2006 Jan; 79(1):35-48. PubMed ID: 16413240
[TBL] [Abstract][Full Text] [Related]
5. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects.
Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF; Elbaek K; Sindrup SH
Eur J Clin Pharmacol; 1996; 51(3-4):289-95. PubMed ID: 9010701
[TBL] [Abstract][Full Text] [Related]
6. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 phenotype-specific codeine population pharmacokinetics.
Linares OA; Fudin J; Schiesser WE; Daly Linares AL; Boston RC
J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):4-15. PubMed ID: 25562725
[TBL] [Abstract][Full Text] [Related]
8. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.
Yue QY; Svensson JO; Alm C; Sjöqvist F; Säwe J
Br J Clin Pharmacol; 1989 Dec; 28(6):639-45. PubMed ID: 2611086
[TBL] [Abstract][Full Text] [Related]
9. The pharmacogenetics of codeine hypoalgesia.
Sindrup SH; Brøsen K
Pharmacogenetics; 1995 Dec; 5(6):335-46. PubMed ID: 8845855
[TBL] [Abstract][Full Text] [Related]
10. The effect of codeine on gastrointestinal transit in extensive and poor metabolisers of debrisoquine.
Hasselström J; Yue QY; Säwe J
Eur J Clin Pharmacol; 1997; 53(2):145-8. PubMed ID: 9403287
[TBL] [Abstract][Full Text] [Related]
11. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation.
Eckhardt K; Li S; Ammon S; Schänzle G; Mikus G; Eichelbaum M
Pain; 1998 May; 76(1-2):27-33. PubMed ID: 9696456
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine.
Yue QY; Hasselström J; Svensson JO; Säwe J
Br J Clin Pharmacol; 1991 Jun; 31(6):635-42. PubMed ID: 1867957
[TBL] [Abstract][Full Text] [Related]
13. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone.
Dilger K; Hofmann U; Klotz U
Clin Pharmacol Ther; 2000 May; 67(5):512-20. PubMed ID: 10824630
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin.
Roy SD; Hawes EM; McKay G; Korchinski ED; Midha KK
Clin Pharmacol Ther; 1985 Aug; 38(2):128-33. PubMed ID: 4017414
[TBL] [Abstract][Full Text] [Related]
17. On the assessment of drug metabolism by assays of codeine and its main metabolites.
Haffen E; Paintaud G; Berard M; Masuyer C; Bechtel Y; Bechtel PR
Ther Drug Monit; 2000 Jun; 22(3):258-65. PubMed ID: 10850391
[TBL] [Abstract][Full Text] [Related]
18. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.
Mikus G; Trausch B; Rodewald C; Hofmann U; Richter K; Gramatté T; Eichelbaum M
Clin Pharmacol Ther; 1997 Apr; 61(4):459-66. PubMed ID: 9129563
[TBL] [Abstract][Full Text] [Related]
19. Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors.
Thompson CM; Wojno H; Greiner E; May EL; Rice KC; Selley DE
J Pharmacol Exp Ther; 2004 Feb; 308(2):547-54. PubMed ID: 14600248
[TBL] [Abstract][Full Text] [Related]
20. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
Heiskanen T; Olkkola KT; Kalso E
Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
